← Back to Search

Monoclonal Antibodies

PRS-343 for Breast Cancer

Phase 1
Waitlist Available
Research Sponsored by Pieris Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a new drug to see what the maximum tolerated dose is and what the side effects are in patients with HER2+ advanced or metastatic solid tumors.

Eligible Conditions
  • Breast Cancer
  • Gastric Cancer
  • Bladder Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

1Treatment groups
Experimental Treatment
Group I: PRS-343Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PRS-343
2017
Completed Phase 1
~90

Find a Location

Who is running the clinical trial?

Pieris Pharmaceuticals, Inc.Lead Sponsor
3 Previous Clinical Trials
166 Total Patients Enrolled
~11 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top